Cardiovascular manifestations of systemic lupus erythematosus: Current perspective
Cardiovascular manifestations develop in the majority of SLE patients at some time during the course of their illness, the most common being acute fibrinous pericarditis and pericardial effusion. Echocardiography has demonstrated an increased incidence of pericardial effusion, even in those who have...
Gespeichert in:
Veröffentlicht in: | Progress in cardiovascular diseases 1985-05, Vol.27 (6), p.421-434 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 434 |
---|---|
container_issue | 6 |
container_start_page | 421 |
container_title | Progress in cardiovascular diseases |
container_volume | 27 |
creator | Ansari, Azam Larson, Paul H. Bates, Henry D. |
description | Cardiovascular manifestations develop in the majority of SLE patients at some time during the course of their illness, the most common being acute fibrinous pericarditis and pericardial effusion. Echocardiography has demonstrated an increased incidence of pericardial effusion, even in those who have minimal symptoms. Chronic adhesive pericarditis, pericardial tamponade, and constrictive pericarditis occur rarely. While myocarditis is commonly noted at autopsy, it is often silent clinically. Diagnosis during life can be confirmed only by endomyocardial biopsy. Electrocardiographic changes are often nonspecific. Endocarditis with superimposed nonbacterial verrucous vegetations (Libman-Sacks) is noted in more than 40% of hearts at autopsy, but is rarely diagnosed during life. Valve dysfunctions, such as aortic stenosis, aortic insufficiency, mitral stenosis, and mitral insufficiency, occasionally manifest during life and rarely may necessitate surgery.
Atrial and ventricular arrhythmias, first degree AV block, and acquired CHB occur in association with pericarditis, myocarditis, vasculitis, and myocardial fibrosis, respectively. CCHB developing in newborns of mothers with SLE, particularly those who have an antibody to soluble tissue ribonuclear protein RO(SS-A), is increasingly being appreciated by both pediatric cardiologists and rheumatologists.
Recently, severe coronary atherosclerosis resulting in angina pectoris and/or myocardial infarction in young adults has been noted, particularly in those who had developed risk factors such as hypertension and hyperlipidemia while receiving prolonged corticosteroid therapy. Rarely, coronary arteritis may produce similar symptoms. Congestive heart failure of either single or multiple etiologies carries an ominous prognosis. It remains a cause of high morbidity and mortality unless recognized early and treated properly. Extracardiac vascular manifestations of SLE include telangiectasia, vasculitis, livedo reticularis, Raynaud's phenomena, and thrombophlebitis, all of which may occur either alone or in different combinations.
Evidence is now slowly accumulating that substantiates that immune complex deposition, complement activation and subsequent inflammatory reaction is responsible for the majority of the cardiovascular manifestations of SLE, for example, pericarditis, myocarditis, endocarditis, coronary arteritis, coronary atherosclerosis, and systemic and pulmonary vasculitis. For the pathogenesis of CCHB, a mater |
doi_str_mv | 10.1016/0033-0620(85)90003-9 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76147850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0033062085900039</els_id><sourcerecordid>76147850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-5b9cc940e19df69060ecb103f9ec7f4859f7a341633bc70adaf8363fecca72493</originalsourceid><addsrcrecordid>eNp9kEtLLDEQRoNc0fHxDxR6IaKL1kqnk-64EGTwBYIgug6ZdIWbS79MdQ_Mv7fHGWZ5V0XxnfooDmNnHG44cHULIEQKKoOrUl5rmNZU77EZlyJLS5WLP2y2Qw7ZEdE_AC6hKA7YQVYqUFrP2Mfcxip0S0turG1MGtsGjzTYIXQtJZ1PaEUDNsEl9diPlGBcDX-xsUNHI90l8zFGbIekx0g9uiEs8YTte1sTnm7nMft6evycv6Rv78-v84e31OUyG1K50M7pHJDryisNCtAtOAiv0RU-L6X2hRU5V0IsXAG2sr4USnh0zhZZrsUxu9z09rH7HqefTRPIYV3bFruRTKF4XpQSJjDfgC52RBG96WNobFwZDmat0qw9mbUnU0rzq9Ks-8-3_eOiwWp3tHU35RfbfJJnax9t6wLtMM2FkFk5YfcbDCcXy4DRkAvYOqxCnISZqgv__-MHEpOROA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76147850</pqid></control><display><type>article</type><title>Cardiovascular manifestations of systemic lupus erythematosus: Current perspective</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Ansari, Azam ; Larson, Paul H. ; Bates, Henry D.</creator><creatorcontrib>Ansari, Azam ; Larson, Paul H. ; Bates, Henry D.</creatorcontrib><description>Cardiovascular manifestations develop in the majority of SLE patients at some time during the course of their illness, the most common being acute fibrinous pericarditis and pericardial effusion. Echocardiography has demonstrated an increased incidence of pericardial effusion, even in those who have minimal symptoms. Chronic adhesive pericarditis, pericardial tamponade, and constrictive pericarditis occur rarely. While myocarditis is commonly noted at autopsy, it is often silent clinically. Diagnosis during life can be confirmed only by endomyocardial biopsy. Electrocardiographic changes are often nonspecific. Endocarditis with superimposed nonbacterial verrucous vegetations (Libman-Sacks) is noted in more than 40% of hearts at autopsy, but is rarely diagnosed during life. Valve dysfunctions, such as aortic stenosis, aortic insufficiency, mitral stenosis, and mitral insufficiency, occasionally manifest during life and rarely may necessitate surgery.
Atrial and ventricular arrhythmias, first degree AV block, and acquired CHB occur in association with pericarditis, myocarditis, vasculitis, and myocardial fibrosis, respectively. CCHB developing in newborns of mothers with SLE, particularly those who have an antibody to soluble tissue ribonuclear protein RO(SS-A), is increasingly being appreciated by both pediatric cardiologists and rheumatologists.
Recently, severe coronary atherosclerosis resulting in angina pectoris and/or myocardial infarction in young adults has been noted, particularly in those who had developed risk factors such as hypertension and hyperlipidemia while receiving prolonged corticosteroid therapy. Rarely, coronary arteritis may produce similar symptoms. Congestive heart failure of either single or multiple etiologies carries an ominous prognosis. It remains a cause of high morbidity and mortality unless recognized early and treated properly. Extracardiac vascular manifestations of SLE include telangiectasia, vasculitis, livedo reticularis, Raynaud's phenomena, and thrombophlebitis, all of which may occur either alone or in different combinations.
Evidence is now slowly accumulating that substantiates that immune complex deposition, complement activation and subsequent inflammatory reaction is responsible for the majority of the cardiovascular manifestations of SLE, for example, pericarditis, myocarditis, endocarditis, coronary arteritis, coronary atherosclerosis, and systemic and pulmonary vasculitis. For the pathogenesis of CCHB, a maternal antibody to the soluble tissue ribonuclear protein RO(SS-A), which crosses the placenta during the early stage of gestation and either interferes with the development or afflicts a degenerating process in the developing conduction system, is being incriminated.
Corticosteroid therapy remains the cornerstone for the management of pericarditis, myocarditis, vasculitis, and coronary arteritis. However, nonsteroidal inflammatory agents, antiarrhythmic drugs, antihypertensive agents, vasodilator drugs, intensive endocarditis prophylaxis, and rarely, intracardiac pacing when indicated also play an important role in the overall management of cardiovascular manifestations of SLE.
Renal failure, lupus cerebritis, and infections are still the three most common causes of death in patients with SLE. However, recently increased cardiac mortality as a result of hypertension, congestive heart failure, coronary atherosclerosis, and thrombosis, the latter particularly in young women, has been recognized. Mortality of infants with CCHB born to mothers with SLE remains significant despite intracardiac pacing.</description><identifier>ISSN: 0033-0620</identifier><identifier>EISSN: 1532-8643</identifier><identifier>DOI: 10.1016/0033-0620(85)90003-9</identifier><identifier>PMID: 2860699</identifier><identifier>CODEN: PCVDAN</identifier><language>eng</language><publisher>Philadelphia, PA: Elsevier Inc</publisher><subject>Adrenal Cortex Hormones - adverse effects ; Adrenal Cortex Hormones - therapeutic use ; Adrenergic alpha-Antagonists - therapeutic use ; Adult ; Anti-Inflammatory Agents - therapeutic use ; Antigen-Antibody Complex ; Biological and medical sciences ; Diagnosis, Differential ; Echocardiography ; Electrocardiography ; Endocarditis - etiology ; Endocarditis - pathology ; Female ; Heart Diseases - diagnosis ; Heart Diseases - etiology ; Heart Diseases - pathology ; Humans ; Hypertension - drug therapy ; Hypertension - etiology ; Infant, Newborn ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - drug therapy ; Male ; Medical sciences ; Myocarditis - etiology ; Myocarditis - pathology ; Pericarditis - drug therapy ; Pericarditis - etiology ; Pericarditis - pathology ; Prognosis ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Vascular Diseases - etiology ; Vascular Diseases - pathology</subject><ispartof>Progress in cardiovascular diseases, 1985-05, Vol.27 (6), p.421-434</ispartof><rights>1985</rights><rights>1985 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-5b9cc940e19df69060ecb103f9ec7f4859f7a341633bc70adaf8363fecca72493</citedby><cites>FETCH-LOGICAL-c452t-5b9cc940e19df69060ecb103f9ec7f4859f7a341633bc70adaf8363fecca72493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0033062085900039$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9133528$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2860699$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ansari, Azam</creatorcontrib><creatorcontrib>Larson, Paul H.</creatorcontrib><creatorcontrib>Bates, Henry D.</creatorcontrib><title>Cardiovascular manifestations of systemic lupus erythematosus: Current perspective</title><title>Progress in cardiovascular diseases</title><addtitle>Prog Cardiovasc Dis</addtitle><description>Cardiovascular manifestations develop in the majority of SLE patients at some time during the course of their illness, the most common being acute fibrinous pericarditis and pericardial effusion. Echocardiography has demonstrated an increased incidence of pericardial effusion, even in those who have minimal symptoms. Chronic adhesive pericarditis, pericardial tamponade, and constrictive pericarditis occur rarely. While myocarditis is commonly noted at autopsy, it is often silent clinically. Diagnosis during life can be confirmed only by endomyocardial biopsy. Electrocardiographic changes are often nonspecific. Endocarditis with superimposed nonbacterial verrucous vegetations (Libman-Sacks) is noted in more than 40% of hearts at autopsy, but is rarely diagnosed during life. Valve dysfunctions, such as aortic stenosis, aortic insufficiency, mitral stenosis, and mitral insufficiency, occasionally manifest during life and rarely may necessitate surgery.
Atrial and ventricular arrhythmias, first degree AV block, and acquired CHB occur in association with pericarditis, myocarditis, vasculitis, and myocardial fibrosis, respectively. CCHB developing in newborns of mothers with SLE, particularly those who have an antibody to soluble tissue ribonuclear protein RO(SS-A), is increasingly being appreciated by both pediatric cardiologists and rheumatologists.
Recently, severe coronary atherosclerosis resulting in angina pectoris and/or myocardial infarction in young adults has been noted, particularly in those who had developed risk factors such as hypertension and hyperlipidemia while receiving prolonged corticosteroid therapy. Rarely, coronary arteritis may produce similar symptoms. Congestive heart failure of either single or multiple etiologies carries an ominous prognosis. It remains a cause of high morbidity and mortality unless recognized early and treated properly. Extracardiac vascular manifestations of SLE include telangiectasia, vasculitis, livedo reticularis, Raynaud's phenomena, and thrombophlebitis, all of which may occur either alone or in different combinations.
Evidence is now slowly accumulating that substantiates that immune complex deposition, complement activation and subsequent inflammatory reaction is responsible for the majority of the cardiovascular manifestations of SLE, for example, pericarditis, myocarditis, endocarditis, coronary arteritis, coronary atherosclerosis, and systemic and pulmonary vasculitis. For the pathogenesis of CCHB, a maternal antibody to the soluble tissue ribonuclear protein RO(SS-A), which crosses the placenta during the early stage of gestation and either interferes with the development or afflicts a degenerating process in the developing conduction system, is being incriminated.
Corticosteroid therapy remains the cornerstone for the management of pericarditis, myocarditis, vasculitis, and coronary arteritis. However, nonsteroidal inflammatory agents, antiarrhythmic drugs, antihypertensive agents, vasodilator drugs, intensive endocarditis prophylaxis, and rarely, intracardiac pacing when indicated also play an important role in the overall management of cardiovascular manifestations of SLE.
Renal failure, lupus cerebritis, and infections are still the three most common causes of death in patients with SLE. However, recently increased cardiac mortality as a result of hypertension, congestive heart failure, coronary atherosclerosis, and thrombosis, the latter particularly in young women, has been recognized. Mortality of infants with CCHB born to mothers with SLE remains significant despite intracardiac pacing.</description><subject>Adrenal Cortex Hormones - adverse effects</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Adrenergic alpha-Antagonists - therapeutic use</subject><subject>Adult</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antigen-Antibody Complex</subject><subject>Biological and medical sciences</subject><subject>Diagnosis, Differential</subject><subject>Echocardiography</subject><subject>Electrocardiography</subject><subject>Endocarditis - etiology</subject><subject>Endocarditis - pathology</subject><subject>Female</subject><subject>Heart Diseases - diagnosis</subject><subject>Heart Diseases - etiology</subject><subject>Heart Diseases - pathology</subject><subject>Humans</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - etiology</subject><subject>Infant, Newborn</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Myocarditis - etiology</subject><subject>Myocarditis - pathology</subject><subject>Pericarditis - drug therapy</subject><subject>Pericarditis - etiology</subject><subject>Pericarditis - pathology</subject><subject>Prognosis</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Vascular Diseases - etiology</subject><subject>Vascular Diseases - pathology</subject><issn>0033-0620</issn><issn>1532-8643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLLDEQRoNc0fHxDxR6IaKL1kqnk-64EGTwBYIgug6ZdIWbS79MdQ_Mv7fHGWZ5V0XxnfooDmNnHG44cHULIEQKKoOrUl5rmNZU77EZlyJLS5WLP2y2Qw7ZEdE_AC6hKA7YQVYqUFrP2Mfcxip0S0turG1MGtsGjzTYIXQtJZ1PaEUDNsEl9diPlGBcDX-xsUNHI90l8zFGbIekx0g9uiEs8YTte1sTnm7nMft6evycv6Rv78-v84e31OUyG1K50M7pHJDryisNCtAtOAiv0RU-L6X2hRU5V0IsXAG2sr4USnh0zhZZrsUxu9z09rH7HqefTRPIYV3bFruRTKF4XpQSJjDfgC52RBG96WNobFwZDmat0qw9mbUnU0rzq9Ks-8-3_eOiwWp3tHU35RfbfJJnax9t6wLtMM2FkFk5YfcbDCcXy4DRkAvYOqxCnISZqgv__-MHEpOROA</recordid><startdate>198505</startdate><enddate>198505</enddate><creator>Ansari, Azam</creator><creator>Larson, Paul H.</creator><creator>Bates, Henry D.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198505</creationdate><title>Cardiovascular manifestations of systemic lupus erythematosus: Current perspective</title><author>Ansari, Azam ; Larson, Paul H. ; Bates, Henry D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-5b9cc940e19df69060ecb103f9ec7f4859f7a341633bc70adaf8363fecca72493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Adrenal Cortex Hormones - adverse effects</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Adrenergic alpha-Antagonists - therapeutic use</topic><topic>Adult</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antigen-Antibody Complex</topic><topic>Biological and medical sciences</topic><topic>Diagnosis, Differential</topic><topic>Echocardiography</topic><topic>Electrocardiography</topic><topic>Endocarditis - etiology</topic><topic>Endocarditis - pathology</topic><topic>Female</topic><topic>Heart Diseases - diagnosis</topic><topic>Heart Diseases - etiology</topic><topic>Heart Diseases - pathology</topic><topic>Humans</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - etiology</topic><topic>Infant, Newborn</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Myocarditis - etiology</topic><topic>Myocarditis - pathology</topic><topic>Pericarditis - drug therapy</topic><topic>Pericarditis - etiology</topic><topic>Pericarditis - pathology</topic><topic>Prognosis</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Vascular Diseases - etiology</topic><topic>Vascular Diseases - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ansari, Azam</creatorcontrib><creatorcontrib>Larson, Paul H.</creatorcontrib><creatorcontrib>Bates, Henry D.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in cardiovascular diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ansari, Azam</au><au>Larson, Paul H.</au><au>Bates, Henry D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiovascular manifestations of systemic lupus erythematosus: Current perspective</atitle><jtitle>Progress in cardiovascular diseases</jtitle><addtitle>Prog Cardiovasc Dis</addtitle><date>1985-05</date><risdate>1985</risdate><volume>27</volume><issue>6</issue><spage>421</spage><epage>434</epage><pages>421-434</pages><issn>0033-0620</issn><eissn>1532-8643</eissn><coden>PCVDAN</coden><abstract>Cardiovascular manifestations develop in the majority of SLE patients at some time during the course of their illness, the most common being acute fibrinous pericarditis and pericardial effusion. Echocardiography has demonstrated an increased incidence of pericardial effusion, even in those who have minimal symptoms. Chronic adhesive pericarditis, pericardial tamponade, and constrictive pericarditis occur rarely. While myocarditis is commonly noted at autopsy, it is often silent clinically. Diagnosis during life can be confirmed only by endomyocardial biopsy. Electrocardiographic changes are often nonspecific. Endocarditis with superimposed nonbacterial verrucous vegetations (Libman-Sacks) is noted in more than 40% of hearts at autopsy, but is rarely diagnosed during life. Valve dysfunctions, such as aortic stenosis, aortic insufficiency, mitral stenosis, and mitral insufficiency, occasionally manifest during life and rarely may necessitate surgery.
Atrial and ventricular arrhythmias, first degree AV block, and acquired CHB occur in association with pericarditis, myocarditis, vasculitis, and myocardial fibrosis, respectively. CCHB developing in newborns of mothers with SLE, particularly those who have an antibody to soluble tissue ribonuclear protein RO(SS-A), is increasingly being appreciated by both pediatric cardiologists and rheumatologists.
Recently, severe coronary atherosclerosis resulting in angina pectoris and/or myocardial infarction in young adults has been noted, particularly in those who had developed risk factors such as hypertension and hyperlipidemia while receiving prolonged corticosteroid therapy. Rarely, coronary arteritis may produce similar symptoms. Congestive heart failure of either single or multiple etiologies carries an ominous prognosis. It remains a cause of high morbidity and mortality unless recognized early and treated properly. Extracardiac vascular manifestations of SLE include telangiectasia, vasculitis, livedo reticularis, Raynaud's phenomena, and thrombophlebitis, all of which may occur either alone or in different combinations.
Evidence is now slowly accumulating that substantiates that immune complex deposition, complement activation and subsequent inflammatory reaction is responsible for the majority of the cardiovascular manifestations of SLE, for example, pericarditis, myocarditis, endocarditis, coronary arteritis, coronary atherosclerosis, and systemic and pulmonary vasculitis. For the pathogenesis of CCHB, a maternal antibody to the soluble tissue ribonuclear protein RO(SS-A), which crosses the placenta during the early stage of gestation and either interferes with the development or afflicts a degenerating process in the developing conduction system, is being incriminated.
Corticosteroid therapy remains the cornerstone for the management of pericarditis, myocarditis, vasculitis, and coronary arteritis. However, nonsteroidal inflammatory agents, antiarrhythmic drugs, antihypertensive agents, vasodilator drugs, intensive endocarditis prophylaxis, and rarely, intracardiac pacing when indicated also play an important role in the overall management of cardiovascular manifestations of SLE.
Renal failure, lupus cerebritis, and infections are still the three most common causes of death in patients with SLE. However, recently increased cardiac mortality as a result of hypertension, congestive heart failure, coronary atherosclerosis, and thrombosis, the latter particularly in young women, has been recognized. Mortality of infants with CCHB born to mothers with SLE remains significant despite intracardiac pacing.</abstract><cop>Philadelphia, PA</cop><pub>Elsevier Inc</pub><pmid>2860699</pmid><doi>10.1016/0033-0620(85)90003-9</doi><tpages>14</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0033-0620 |
ispartof | Progress in cardiovascular diseases, 1985-05, Vol.27 (6), p.421-434 |
issn | 0033-0620 1532-8643 |
language | eng |
recordid | cdi_proquest_miscellaneous_76147850 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Adrenal Cortex Hormones - adverse effects Adrenal Cortex Hormones - therapeutic use Adrenergic alpha-Antagonists - therapeutic use Adult Anti-Inflammatory Agents - therapeutic use Antigen-Antibody Complex Biological and medical sciences Diagnosis, Differential Echocardiography Electrocardiography Endocarditis - etiology Endocarditis - pathology Female Heart Diseases - diagnosis Heart Diseases - etiology Heart Diseases - pathology Humans Hypertension - drug therapy Hypertension - etiology Infant, Newborn Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - drug therapy Male Medical sciences Myocarditis - etiology Myocarditis - pathology Pericarditis - drug therapy Pericarditis - etiology Pericarditis - pathology Prognosis Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Vascular Diseases - etiology Vascular Diseases - pathology |
title | Cardiovascular manifestations of systemic lupus erythematosus: Current perspective |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T03%3A58%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiovascular%20manifestations%20of%20systemic%20lupus%20erythematosus:%20Current%20perspective&rft.jtitle=Progress%20in%20cardiovascular%20diseases&rft.au=Ansari,%20Azam&rft.date=1985-05&rft.volume=27&rft.issue=6&rft.spage=421&rft.epage=434&rft.pages=421-434&rft.issn=0033-0620&rft.eissn=1532-8643&rft.coden=PCVDAN&rft_id=info:doi/10.1016/0033-0620(85)90003-9&rft_dat=%3Cproquest_cross%3E76147850%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76147850&rft_id=info:pmid/2860699&rft_els_id=0033062085900039&rfr_iscdi=true |